4634-09-7

Basic information

• Product Name: (6-PHENYL-3-PYRIDINYL)METHANOL
• Synonyms: (6-PHENYL-3-PYRIDINYL)METHANOL;6-Phenyl-3-pyridineMethanol
• CAS NO: 4634-09-7
• Molecular Formula: C₁₂H₁₁NO
• Molecular Weight: 185.22184
• Mol File: 4634-09-7.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (6-PHENYL-3-PYRIDINYL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (6-PHENYL-3-PYRIDINYL)METHANOL(4634-09-7)
• EPA Substance Registry System: (6-PHENYL-3-PYRIDINYL)METHANOL(4634-09-7)

Safety Data

• Hazardous Substances Data: 4634-09-7(Hazardous Substances Data)

Usage

General Description

(6-Phenyl-3-pyridinyl)methanol, also known as 3-hydroxybenzylpyridinium or Oxoiquinoline, is a chemical compound with the molecular formula C13H11NO. It is a pyridine derivative with a phenyl group and a hydroxyl group attached to the pyridine ring. (6-PHENYL-3-PYRIDINYL)METHANOL is utilized in various chemical and pharmaceutical applications, serving as a building block in the synthesis of a wide range of organic compounds. It has been studied for its potential therapeutic effects, including its role as an antioxidant and its ability to inhibit the growth of certain cancer cells. Additionally, it has been used in the development of new drug candidates and as a versatile intermediate in the manufacturing of agrochemicals and fragrance compounds.

Upstream product

• 63056-20-2 2-phenyl-5-pyridinecarboxaldehyde 
• 29051-44-3 6-phenylpyridine-3-carboxylic acid 
• 21543-49-7 2-Chloro-5-hydroxymethylpyridine 
• 98-80-6 phenylboronic acid 
• 73781-91-6 6-Chloronicotinic acid methyl ester 
• 149806-06-4 6-bromonicotinaldehyde 
• 4634-13-3 methyl 6-phenylnicotinate 
• 57443-68-2 ethyl 6-phenyl-3-pyridinecarboxylate 

Downstream Products

• 212573-56-3 5-(bromomethyl)-2-phenylpyridine 
• 179055-41-5 Cycloheptyl-(6-phenyl-pyridin-3-ylmethyl)-amine 
• 350850-63-4 1-[(4-Cyano-5-methyl-4-phenyl)hexyl]-4-[(6-phenylpyridine-3-yl)methyl]piperazine 
• 5229-40-3 2-phenyl-5-pyridylmethyl chloride 
• 118420-51-2 (E)-N-[4-(4-Benzhydryl-piperazin-1-yl)-butyl]-3-(6-phenyl-pyridin-3-yl)-acrylamide 
• 118420-10-3 (E)-3-(6-Phenyl-pyridin-3-yl)-acrylic acid 
• 63056-20-2 2-phenyl-5-pyridinecarboxaldehyde 

Relevant articles and documents

Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility

Following the approval of delamanid and pretomanid as new drugs to treat drug-resistant tuberculosis, there is now a renewed interest in bicyclic nitroimidazole scaffolds as a source of therapeutics against infectious diseases. We recently described a nitroimidazopyrazinone bicyclic subclass with promising antitubercular and antiparasitic activity, prompting additional efforts to generate analogs with improved solubility and enhanced potency. The key pendant aryl substituent was modified by (i) introducing polar functionality to the methylene linker, (ii) replacing the terminal phenyl group with less lipophilic heterocycles, or (iii) generating extended biaryl side chains. Improved antitubercular and antitrypanosomal activity was observed with the biaryl side chains, with most analogs achieved 2- to 175-fold higher activity than the monoaryl parent compounds, with encouraging improvements in solubility when pyridyl groups were incorporated. This study has contributed to understanding the existing structure-activity relationship (SAR) of the nitroimidazopyrazinone scaffold against a panel of disease-causing organisms to support future lead optimization.

CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS

Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.

5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY

Use of a compound of the formula: wherein R represents a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; X represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -CO-, -CS-, -CR(OR)- or -NR- wherein each of R and R represents a hydrogen atom or a hydrocarbon group which may be substituted, R represents a hydrogen atom or a protective group for a hydroxyl group; m represents an integer of 0 to 3; Y represents an oxygen atom, a sulfur atom, or a group of the formula: -SO-, -SO2-, -NR-, -CONR- or -NRCO- wherein R represents a hydrogen atom or a hydrocarbon group which may be substituted; ring A represents an aromatic ring which may further have 1 to 3 substituents; n represents an integer of 1 to 8; ring B represents a nitrogen-containing 5-membered hetero ring which may further be substituted by an alkyl group; X represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -SO-, -SO2-, -O-SO2- or -NR- wherein R represents a hydrogen atom or a hydrocarbon group which may be substituted; R represents a hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; W represents a bond or a divalent hydrocarbon residue having 1 to 20 carbon atoms; R represents a group of the formula: -OR (R represents a hydrogen atom or a hydrocarbon group which may be substituted) or -NRR (each of R and R, whether identical or not, represents a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, or an acyl group which may be substituted; R and R may bind together to form a ring); or a salt thereof, for the manufacture of a pharmaceutical preparation for preventing or treating syndrome X.